Burney Co. Sells 38,157 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Burney Co. trimmed its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 52.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,476 shares of the specialty pharmaceutical company's stock after selling 38,157 shares during the quarter. Burney Co. owned 0.11% of Collegium Pharmaceutical worth $988,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of COLL. JPMorgan Chase & Co. boosted its stake in Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after purchasing an additional 175,892 shares in the last quarter. Penserra Capital Management LLC purchased a new position in Collegium Pharmaceutical in the third quarter worth about $757,000. Barclays PLC lifted its stake in shares of Collegium Pharmaceutical by 152.2% in the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after buying an additional 45,291 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Collegium Pharmaceutical by 194.5% during the second quarter. Squarepoint Ops LLC now owns 110,338 shares of the specialty pharmaceutical company's stock valued at $3,553,000 after buying an additional 72,874 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Collegium Pharmaceutical during the second quarter valued at approximately $2,285,000.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock traded down $0.11 during mid-day trading on Friday, reaching $33.35. 264,277 shares of the stock traded hands, compared to its average volume of 503,716. Collegium Pharmaceutical, Inc. has a 12-month low of $28.39 and a 12-month high of $42.29. The business's 50-day moving average is $30.54 and its 200-day moving average is $34.09. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a market capitalization of $1.08 billion, a PE ratio of 14.38 and a beta of 0.82.

Analyst Ratings Changes

A number of research firms have commented on COLL. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Wednesday, October 23rd. Piper Sandler restated a "neutral" rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target on the stock in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Collegium Pharmaceutical has an average rating of "Moderate Buy" and a consensus target price of $43.80.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the transaction, the executive vice president now directly owns 119,184 shares in the company, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.98% of the company's stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.